Aug 26, 2009 (SmarTrend(R) News Watch via COMTEX) ----8/26/2009-Schering-Plough (NYSE:SGP) announced that the European Medicines Agency (EMEA) has accepted for review the company's fix-dose combination of mometasone furoate and formoterol fumarate for the treatment of asthma in patients 12 years and older. Schering-Plough also said the EMEA has validated the MAA for nomegestrol acetate (2.5 mg) / 17 beta-estradiol (1.5mg), an oral contraceptive containing a distinctive mixture of a natural estrogen that is the same as the estrogen created by a woman's own body and a selective progestin. "These two regulatory milestones are important steps toward advancing our late-stage pipeline and meeting patient needs. If approved by the EMEA, the mometasone furoate/formoterol fumarate combination would represent an important additional treatment option for physicians and their patients and further strengthen Schering-Plough's portfolio of respiratory products," said Thomas P. Koestler, Ph.D., Executive Vice President and President, Schering-Plough Research Institute. "Schering-Plough is also committed to providing women a variety of birth control options to meet diverse lifestyle needs and choices."

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Copyright, Comtex News Network, Inc. 2009
   
   **********************************************************************
   
   As of Saturday, 08-22-2009 23:59, the latest Comtex SmarTrend� Alert, 
   an automated pattern recognition system, indicated an UPTREND on 
   11-14-2008 for SGP @ $16.19.
   
   For more information on SmarTrend, contact your market data
   provider or go to www.mysmartrend.com
   
   SmarTrend is a registered trademark of Comtex News Network, Inc.
   Copyright � 2004-2009 Comtex News Network, Inc. All rights reserved.